PSA I love You: Prostate Cancer Screening in Ireland
Keywords:
MedicineAbstract
Ireland has the second highest rate of prostate cancer (PCa) in Europe and this is largely due to the increased use of PSA testing in Ireland in recent years. Rapid Access Prostate Cancer Clinics (RAPC) were introduced in 2009, in order to increase the organisation and efficiency of PCa diagnosis in Ireland.
The use of PSA as a screening tool is controversial. At present, there is no evidence for the introduction of widespread, population-based screening for PCa. Two large randomised studies which evaluated the efficacy of PSA testing are examined in this review. These are the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and The European Randomised Study for Prostate Cancer (ERSPC). These studies demonstrated conflicting results. The PLCO reported that there was no evidence that PSA screening reduced PCa-related mortality, while the ERSPC showed PSA screening was associated with a 21% decrease in PCa related mortality.
Following the publication of these trials, the European Association of Urology and the American Urology Association produced new PCa screening guidelines. These guidelines advised against widespread screening programmes but recommended PSA testing in men who met certain criteria (based on age, life expectancy and other risk factors). In Ireland, there are currently very little national guidelines in relation to PCa screening. However, much opportunistic testing occurs and patients often request PSA tests in a GP setting. National guidelines for PSA screening, which are in line with the AUA (American Urology Association) and EAU (European Association of Urology) guidelines, need to be introduced in order to prevent overtreatment and over-diagnosis of asymptomatic prostate cancer.
References
2 National Cancer Registry in Ireland (NCRI) (2013) Cancer in Ireland 2013: Annual Report of the National Cancer Registry. Available at http://www.ncri.ie/publications/statisti- cal-reports/cancer-ireland-2013-annual-report-national-can- cer-registry [Accessed January 7th 2014].
3 National Cancer Registry in Ireland Prostate Cancer Fact Sheet (2013) Available at: http://www.ncri.ie/sites/ncri/ files/factsheets/FACTSHEET_prostate.pdf [Accessed January 7th 2014].
4 McNeal, J.E. Normal and pathologic anatomy of pros- tate. Urology 17, 11-16 (1981).
5 Miller, D.C., Hafez, K.S., Stewart, A., Montie, J.E. & Wei, J.T. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 98, 1169-1178 (2003).
6 Fondrevelle, M.E., et al. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urologic oncology 27, 268-276 (2009).
7 Heidenreich, A., et al. Early detection of prostate can- cer: European Association of Urology recommendation. Europe- an urology 64, 347-354 (2013).
8 Gleason, D.F. Classification of prostatic carcinomas. Cancer chemotherapy reports. Part 1 50, 125-128 (1966).
9 Mottet, N., et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology 59, 572-583 (2011).
10 Lilja, H. A kallikrein-like serine protease in prostatic flu- id cleaves the predominant seminal vesicle protein. The Journal of clinical investigation 76, 1899-1903 (1985).
11 Pienta, K.J. Critical appraisal of prostate-specific anti- gen in prostate cancer screening: 20 years later. Urology 73, S11- 20 (2009).
12 National Cancer Registry. Cancer Trends. Recent trends in prostate cancer. 2011 [cited; Available from: http://www.ncri.ie/ pubs/pubfiles/prostate%20trends.pdf [Accessed January 7th 2013].
13 Hoffman, R.M., et al. Prostate cancer screening deci- sions: results from the National Survey of Medical Decisions (DECISIONS study). Archives of internal medicine 169, 1611-1618 (2009).
14 Moyer, V.A. & Force, U.S.P.S.T. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 157, 120-134 (2012).
15 Andriole, G.L., et al. Mortality results from a rand- omized prostate-cancer screening trial. The New England journal of medicine 360, 1310-1319 (2009).
REVIEWS
16 Schroder, F.H., et al. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine 360, 1320-1328 (2009).
17 Schroder, F.H., et al. Prostate-cancer mortality at 11 years of follow-up. The New England journal of medicine 366, 981-990 (2012).
18 Carter, H.B., et al. Early detection of prostate cancer: AUA Guideline. The Journal of urology 190, 419-426 (2013).
19 Drummond, F.J., Carsin, A.E., Sharp, L. & Comber, H. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Irish journal of medical sci- ence 179, 43-49 (2010).
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
